Local view for "http://purl.org/linkedpolitics/eu/plenary/2015-02-11-Speech-3-929-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20150211.64.3-929-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Mr President, the cost of drugs is increasing, and that is a very simple economic fact. We need to recognise that drug innovation is pivotal to future cure and treatment options – and that comes with cost, of which there are two components: development time and research process. We cannot short circuit that, and we should not even attempt to do so. We have to be realistic. The EU would do well to accept that, historically, interventions have created and exacerbated access eligibility. They have not actually delivered any resolution. Clinical trial interference is a very good example of this.
Additional distortion and disruption from the EU, as colleagues have already mentioned this evening, is not going to help. But let me give Members a list of things that maybe we should be debating this evening. What about parallel imports caused by the eurozone issues? What about stopping penalising UK and European manufacturers of both patent-protected and generic products via the HTA system? What about supporting drug development and innovation in academia and the commercial sectors on a free-market basis? What about preventing access from fraudulent medicines, and what about penalising countries that do not adhere to our patent systems? If we could deal with the inefficiencies of drug waste, drug dumping and patient compliance, we would do an awful lot to help with patient access. ‘Want’, ‘need’ and ‘should have’ for patients can be delivered, but you do not do it by more intervention."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples